2008
Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities.
Berger CL, Heald P, Girardi M, Edelson RL. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. Giornale Italiano Di Dermatologia E Venereologia 2008, 143: 43-54. PMID: 18833050.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAnimalsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsApoptosisBexaroteneClone CellsCytokinesDendritic CellsDiphtheria ToxinGene Expression Regulation, NeoplasticHumansImmunophenotypingInterleukin-2Lymphoma, T-Cell, CutaneousMiceNeoplastic Stem CellsPhotopheresisPUVA TherapyRecombinant Fusion ProteinsTetrahydronaphthalenesT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryConceptsCutaneous T-cell lymphomaSheep red blood cellsT-cell lymphomaNew therapeutic approachesBasic science techniquesRed blood cellsClinical featuresTherapeutic optionsT lymphocytesCell lymphomaTherapeutic approachesClinical practiceImmune systemMalignant cellsTherapeutic opportunitiesBlood cellsPatientsImmunobiologyDiseaseMolecular demonstrationCurrent understandingCellsLymphomaLymphocytesImmunology
2007
A systematic review of the safety of topical therapies for atopic dermatitis
Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M, Hanifin J, Lee P, Margolis D, Paller AS, Piacquadio D, Peterson W, Kaulback K, Fennerty M, Wintroub BU. A systematic review of the safety of topical therapies for atopic dermatitis. British Journal Of Dermatology 2007, 156: 203-221. PMID: 17223859, DOI: 10.1111/j.1365-2133.2006.07538.x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, TopicalAdrenal Cortex HormonesAnti-Bacterial AgentsAnti-Inflammatory AgentsCost of IllnessDermatitis, AtopicHumansImmunosuppressive AgentsConceptsAtopic dermatitisTopical therapyEvidence-based medicine expertsSystematic reviewTopical corticosteroidsMedicine expertsTopical calcineurin inhibitorsCochrane Central RegisterMEDLINE In-ProcessNon-Indexed CitationsDrug Administration studySystemic complicationsCentral RegisterControlled TrialsCalcineurin inhibitorsSystemic exposureTopical agentsIn-ProcessMorbid diseaseAD therapyOvid MEDLINEInclusion criteriaTherapyRecent FoodAdministration studies